Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 3079935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

  1984cited by this paper
• Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.

  1983cited by this paper
• Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive.

  1981cited by this paper
• Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man.

  1980cited by this paper
• Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

  1980cited by this paper
• Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone.

  1979cited by this paper
• The Veterans' Administration Cooperative Urological Research Group studies of carcinoma of the prostate: a review.

  1975cited by this paper
• Synthesis and biological properties of (Leu-6)-LH-RH and (D-Leu-6,desGly-NH210)-LH-RH ethylamide.

  1974cited by this paper
• QUANTITATIVE STUDIES OF PROSTATIC SECRETION

  1940cited by this paper

• Advances with androgen deprivation therapy for prostate cancer

  2022cites this paper
• Role of Hormonal Manipulation in Prostate Cancer Management

  2018cites this paper
• Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study.

  2016cites this paper
• First, do no harm, second, do some good, third, give choice and fourth, save cash: the 1, 2, 3 and 4 of transdermal oestradiol as androgen deprivation therapy ticks all the boxes

  2016cites this paper
• Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer

  2015cites this paper
• Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture

  2015cites this paper
• RE: STATE-OF-THE-ART TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER - FORWARD TO THE PAST - AGAIN

  2015cites this paper
• Risk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population

  2015cites this paper
• Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

  2014cites this paper
• Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.

  2014cites this paper
• Parenteral oestrogen: Effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?

  2014cites this paper
• Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications

  2013cites this paper
• Comment on ‘Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'

  2013cites this paper
• Prostate cancer and metabolic syndrome: is there a link?

  2012cites this paper
• Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

  2010cites this paper
• Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors

  2008cites this paper
• Cancer of unknown primary site.

  2008cites this paper
• Androgen deprivation therapy for prostate cancer: new concepts and concerns

  2007cites this paper
• Use of hormonal therapy in men with metastatic prostate cancer.

  2005cites this paper
• Therapy Insight: osteoporosis during hormone therapy for prostate cancer

  2005cites this paper
• Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.

  2004cites this paper
• Diagnosis and management of treatment‐related osteoporosis in men with prostate carcinoma

  2003cites this paper
• Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma

  2003cites this paper
• LEUPRORELIN ACETATE IN PROSTATE CANCER: A EUROPEAN UPDATE

  2002influential citation
• Colorectal Cancer

  2002influential citation
• Prostate cancer

  2002cites this paper
• Emerging pharmacologic therapies for prostate cancer.

  2001cites this paper
• Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer

  2000cites this paper
• Systemic treatment for prostate cancer.

  1998cites this paper
• [Advanced prostatic carcinoma--which hormone therapy when?].

  1995cites this paper
• Leuprorelin

  1994cites this paper
• Hormonal management of prostate cancer

  1992cites this paper
• Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma.

  1991cites this paper
• Gonadotrophin-releasing hormone: physiological significance and relevance to cancer.

  1991cites this paper
• Effect of the new potent LHRH antagonist antide.

  1990cites this paper
• Three-monthly GnRH agonist (buserelin) for prostatic cancer.

  1990cites this paper
• Induction of chemical castration in male rats by a new long‐acting LHRH‐antagonist

  1990cites this paper
• Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.

  1990cites this paper
• 3.75 and 7.5 mg Leuprorelin Acetate Depot in the Treatment of Advanced Prostatic Cancer: Preliminary Report

  1990cites this paper
• Prostate cancer: a model of cancer in the elderly.

  1989cites this paper
• USE OF A GONADOTROPINRELEASING HORMONE AGONIST ANALOGUE FOR TREATMENT OF CYCLIC AUDITORY DYSFUNCTION

  1989cites this paper
• Hormonal Therapy for Advanced Prostatic Carcinoma

  1989cites this paper
• Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.

  1989cites this paper
• Long-term experience with flutamide in patients with prostatic carcinoma.

  1989cites this paper
• Gonadotrophin releasing hormone analogues for prostatic cancer: an overview.

  1988cites this paper
• Treatment of advanced prostatic cancer.

  1987cites this paper
• Luteinizing Hormone - Releasing Hormone Analogs: Development and Mechanism of Action

  1987cites this paper
• Gonadotrophin hormone releasing analogues open new doors in cancer treatment.

  1987cites this paper